Valirx eyes partnerships as first VAL201 study hits the mark
Roche Inks €380M Inflazome Deal, Boosting Inflammation Pipeline
J&J Covid-19 Vaccine Trial Shows ‘Strong’ Immune Response; Street Says Buy
The window is wide open as four more biotechs join the go-go IPO class of 2020
Vaxart: Watch Out for This Underdog in the COVID-19 Vaccine Race
RedHill Gets Brazil’s Nod For Covid-19 Study With Opaganib
Fourth large-scale COVID-19 vaccine trial begins in the United States
Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 50%
CSU secures $3.1 million from NIH to advance SolaVAX coronavirus vaccine research
SARS-CoV-2 infection can block pain, opening up unexpected new possibilities for research into pain relief medication
Wells Fargo: These 2 Stocks Could Deliver Triple-Digit Wins
Moderna broadens R&D scope with Vertex, Chiesi alliances
BioNTech Buys German Site From Novartis To Boost Covid-19 Vaccine Supply
Sorrento Pops 28% On FDA Nod To Kick Off Covid-19 Antibody Trial
iBio’s FastPharming Platform Produces Decoy Therapeutic to Bind to SARS-CoV-2
News briefing: Top FDA official exits; Sun Genomics closes $9.25M Series A
Marinus Spikes 63% On Positive Phase 3 Trial For Rare Genetic Epilepsy
Beyond the Spike: The COVAXX Approach to a COVID-19 Vaccine
A bifidobacterial protein that can reduce inflammation in COVID-19 found by a RUDN geneticist
GSK and J&J alum Vijay Reddy to take control of R&D at Tmunity; Andrew Hirsch exits Agios for CEO job at C4 Therapeutics
Exclusive: Ginkgo teams with unknown upstart in hunt for Covid-19 antibody
Non-vaccine nasal spray could protect against COVID-19
Early data shows Russia’s Sputnik V COVID-19 vaccine produces immune response
Researchers identify nanobody that may prevent COVID-19 infection
J&J Abandons Influenza A Treatment Program After Interim Analysis
A ‘Human’ Touch vs. COVID-19
Well Fargo Says These 2 Stocks Could Rally Over 70% From Current Levels
Finding cortisone alternatives with fewer side effects
GSK and Vir take COVID-19 antibody therapy into clinic
Oppenheimer: These 3 Penny Stocks Have Triple-Digit Upside Potential